The cellular prion protein (PrPC) as neuronal receptor for α-synuclein

Laura Urreaa,b,c,d, Isidro Ferrerd,e,f,g, Rosalina Gavín3,4,a,b,c,d, and José Antonio del Río3,4,a,b,c,d

aMolecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Barcelona, Spain;

bDepartment of Cell Biology, Physiology and Immunology, University of Barcelona, Barcelona, Spain;

cCenter for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain;

dInstitute of Neuroscience, University of Barcelona, Barcelona, Spain;

eDepartment of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona, Spain;

fSenior Consultant Neuropathology, Service of Pathology, Bellvitge University Hospital, Hospital de Llobregat, Spain;

gCenter for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Hospitalet de Llobregat, Spain

ABSTRACT. The term ‘prion-like’ is used to define some misfolded protein species that propagate intercellularly, triggering protein aggregation in recipient cells. For cell binding, both direct plasma membrane interaction and membrane receptors have been described for particular amyloids. In this respect, emerging evidence demonstrates that several β-sheet enriched proteins can bind to the cellular prion protein (PrPC). Among other interactions, the physiological relevance of the binding between β-amloid and PrPC has been a relevant focus of numerous studies. At the molecular level, published data point to the second charged cluster domain of the PrPC molecule as the relevant binding domain of the β-amloid/PrPC interaction. In addition to β-amloid, participation of PrPC in binding α-synuclein, responsible for neurodegenerative synucleopathies, has been reported. Although results indicate relevant participation of PrPC in the spreading of α-synuclein in living mice, the physiological relevance of the interaction remains elusive. In this comment, we focus our attention on summarizing current knowledge of PrPC as a receptor for amyloid proteins and its physiological significance, with particular focus on α-synuclein.

KEYWORDS. α-synuclein, charged cluster domain, interneuronal transport, LAG3, neurodegeneration, PrPC, Parkinson disease

Correspondence to: Laura Urrea; Molecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri Reixac 15–21, E-08028 Barcelona, Spain; Email: lurrea@ibecbarcelona.eu; José Antonio del Río, Molecular and Cellular Neurobiotechnology, Institute of Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, Baldiri Reixac 15—21, E-08028 Barcelona, Spain; Email: jadelrio@ibecbarcelona.eu

Extra View to: Urrea L, Segura-Feliu M, Masuda-Suzukake M, Hervera A, Pedraz L, García Aznar JM, Vila M, Samitier J, Torrents E, Ferrer I, et al. Involvement of cellular prion protein in α-synuclein transport in neurons. Mol Neurobiol 2017; [epublished ahead of print]; https://doi.org/10.1007/s12035-017-0451-4

Received May 1, 2017; Revised May 19, 2017; Accepted May 19, 2017.
Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide. Motor disabilities, globally called parkinsonism, are characteristic of the disorder; these may be preceded by neurovegetative symptoms, sleep disorders, and loss of olfaction; neurocognitive deficits may also appear with disease progression leading to dementia (i.e., Parkinson disease dementia, PDD). Histologically, PD is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, which is causative of parkinsonism, and the presence of intraneuronal insoluble inclusions called Lewy Bodies (LB) and Lewy Neurites (LN) in several brain regions. LB/LN aggregates contain various misfolded proteins such as ubiquitin, tau, and lipids but their major component is hyperphosphorylated α-synuclein. Abnormal α-synuclein aggregates appear, in addition to PD, in various α-synucleinopathies such as Dementia with Lewy Bodies (DLB) and multiple system atrophy (MSA). In these disorders, aggregates are deposited in the brain in a filamentous form displaying a β-sheet structure which is abnormally phosphorylated at Serine129 and is also ubiquitinated. In addition, PDD, and particularly, DLB post-mortem brains often display accumulations of β-amyloid forming diffuse and neuritic plaques, and neurofibrillary tangles composed of abnormally hyperphosphorylated tau. In addition, the potential contribution of α-synuclein to Alzheimer disease (AD) pathology is considered important today, with ≈ 40% of AD cases presenting LB/LN, often as amygdala-predominant Lewy body disease (LBD).

‘PRION-LIKE’ PROTEINS AND NEURONAL SPREADING

Most of the above-mentioned misfolded proteins (i.e., β-amyloid, hyperphosphorylated tau, and abnormal α-synuclein) are able to ‘propagate’ or ‘spread’ between cells in the same manner as infectious prions, a mechanism termed ‘prion-like’, ‘prionoid’, or simply ‘prions’ in several studies. However, not all the molecular properties of infectious prions observed in transmissible spongiform encephalopathies (TSEs) have been demonstrated in these proteinaceous species. The infectious spreading of pathogenic prions occurs between cells, tissues and, more relevantly, organisms. This is not described for all ‘prion-like’ molecules. As recently indicated by Harbi and Harrison in Prion, ‘prion-like activity’ or ‘prion-like propagation’ may also refer to self-propagating protein aggregates that may not yet meet a stricter ‘prion’ definition. The term ‘prion-like’ for the ‘propagative’ activities of the misfolded proteins will be used in the present article. Moreover, in our review misfolded α-synuclein protein becomes a ‘prion-like’ protein.

Although there is some disagreement, it is well established that the disease progression of some neurodegenerative disorders, such as AD and PD, seems to correlate with brain propagation of the misfolded protein between predictable anatomical pathways. In PD and DLB, the sequential accumulation of α-synuclein starts in the olfactory bulb, medulla oblongata, midbrain and forebrain, and neocortex. Indeed, the spreading of pathological α-synuclein is closely correlated with disease progression and is considered to be the underlying mechanism of progression of the disease. Extensive research has demonstrated that spreading of α-synuclein can also be reproduced in vivo and in vitro. In vivo, peripheral (i.e., intracerebral injections of recombinant α-synuclein protofibrils or insoluble fractions of α-synuclein derived from affected brains trigger conversion of natural endogenous α-synuclein into the abnormal misfolded form, and this misfolded α-synuclein propagates in the brains of wild-type mice, α-synuclein transgenic mice, monkeys, and marmosets. In vitro experiments, and more relevantly, the emerging development of ‘lab-on-a-chip’ device cultures based on microfluidics, have been of great value in helping to determine the cell-to-cell transport of several amyloids including α-synuclein (i.e., α-synuclein fibrils as well as LB extracts can spread between neurons and astroglial cells growing in these devices. Several mechanisms have been reported
for α-synuclein spreading using these or other in vitro methods, such as extracellular vesicles and tunneling nanotubes (TNTs).\textsuperscript{13,30-35} In addition to these descriptions, several groups have started to measure the presence of membrane receptors for α-synuclein and/or other amyloids.

**A CHARGED DOMAIN OF PRPC IS A COMMON ‘DOCKING-DOMAIN’ FOR SEVERAL ‘PRION-LIKE’ PROTEINACEOUS SPECIES**

Several studies have reported that β-sheet rich amyloid proteins (including α-synuclein) can interact with plasma membrane (e.g.,\textsuperscript{36}). Although this interaction might be involved in amyloid internalization leading to cytotoxicity, ‘docking’ and receptor-mediated interaction activities at plasma membrane might support most of the physiological activities of oligomeric proteinaceous species.\textsuperscript{37} PrPC can bind with numerous membrane-associated molecules including adhesion molecules, growth-factor receptors, and neurotransmitter receptors, among others. More relevantly, PrPC has been described as a high-affinity binding partner of oligomeric β-amyloid (Aβo)—a relevant finding in determining the early trigger in AD.\textsuperscript{38-43} However, this interaction (Aβo-PrPC) is not exclusive since other studies have determined that the N-terminal domain of PrPC can bind to several β-rich peptides, including Aβ.\textsuperscript{44,45} Indeed, mapping studies point to the 90–110 amino acids located in the second charged cluster of PrPC as the main residues responsible for Aβo binding (see for a recent description of PrPC domains). Although interaction between PrPC and Aβo has been demonstrated in several studies,\textsuperscript{38-43} some observations indicate that PrPC is not a mediator of the neurotoxic effects of Aβo (i.e.,\textsuperscript{48-51}). Starting from these pioneering PrPC-Aβo binding descriptions, several laboratories have started to analyze whether PrPC may also be a ‘cellular partner’ for other proteinaceous species displaying ‘propagative’ properties, and to determine whether PrPC participates in or regulates the spreading of these ‘prion-like’ proteins and their associated neuropathology. Results published recently by our group point out that, in addition to Aβo, membrane-anchored PrPC can also bind to α-synuclein fibers.\textsuperscript{27}

Several receptors have been described as binding α-synuclein. It has been shown that α-synuclein binds to Na\textsuperscript{+}/K\textsuperscript{+}-ATPase subunit α3,\textsuperscript{52} lymphocyte-activation gene 3 (LAG3),\textsuperscript{53} neurexin,\textsuperscript{52,53} amyloid β precursor-like protein 1 (APLP1),\textsuperscript{55} and PrPC.\textsuperscript{27} Although α-synuclein is implicated in the binding, uptake, and/or trafficking of α-synuclein protofibrils, some details of the process are missing, and for most of them except LAG3 and PrPC, their putative participation in the spreading of α-synuclein and interneuronal transport has not been fully investigated. For LAG3 and PrPC, their binding and participation in α-synuclein expansion has been analyzed in vitro and in vivo.\textsuperscript{27,53} In both cases, the absence of the protein receptor (LAG3 or PrPC) largely decreases but does not fully impair α-synuclein spreading in vivo.\textsuperscript{27,53} Recent unpublished from our group noted that this decrease in α-synuclein spreading in the absence of PrPC may occur in different strains of mice lacking functional PrPC, by avoiding an indirect effect of the ‘Prnp-flanking genes’ observed in the Zurich I (ZH1)-derived mice\textsuperscript{47,54,55} (Fig. 1). Conversely, the overexpression of Prnp enhances α-synuclein spreading and the generation of the phosphorylated form of α-synuclein (p-α-synuclein) in anatomically connected regions (i.e., striatum → motor cortex) (Fig. 1c). These results were obtained using different Prnp genotypes, Prnp\textsuperscript{+/+} and Prnp\textsuperscript{0/0} (B6.129 (ZH1) Prnp\textsuperscript{0/0} 27 and Zurich 3 (ZH3) Prnp\textsuperscript{0/0} mice\textsuperscript{54}), and Tga20 (Prnp-overexpressing) mice under a B6.129 background\textsuperscript{27} (Fig. 1).

**TOWARD UNCOVERING OF THE PHYSIOLOGICAL RELEVANCE OF α-SYNUCLEIN-PRPC INTERACTION: LAST-MINUTE QUESTIONS**

Although the interaction between α-synuclein and PrPC has been described, as has a
correlation between *Prnp* expression and p-α-synuclein spreading *in vitro* and *in vivo*, new, challenging questions have emerged. Several open questions at both the cellular level and that of neurodegeneration warrant further study:

i) α-Synuclein can be transported intercellularly through several mechanisms. However, the participation of PrP^C^ in α-synuclein seeding properties and particular transport mechanisms needs further research.

ii) Astroglial cells participate in α-synuclein spreading.26 Since PrP^C^ is expressed in neurons and glial cells,56 PrP^C^ might also play a role in α-synuclein glia-to-neuron transmission.

iii) The putative participation of PrP^C^ in the neurotoxic effects of α-synuclein calls for further attention. Conversely, the actions of this binding in PrP^C^ biology and physiology, both healthy and unhealthy, are still unknown.

iv) The vast majority of PD patients are sporadic, but mutations in the SNCA gene encoding α-synuclein A53T, A30P, E46K, A53E, H50Q, and G51D cause autosomal-dominant forms of PD.57 As the α-synuclein/PrP^C^ interaction takes place in the second charged cluster of the PrP^C^, the question of whether these point mutations may alter α-synuclein/PrP^C^ interaction needs to be addressed.

v) α-synuclein protofibrils bind to PrP^C^ in their second charged cluster domain, sharing this binding motif with Aβo. This suggests that the effort to block PrP^C^/Aβo interaction with molecules (i.e., antibodies58) or chemical compounds could also be a potential therapeutic intervention for α-synuclein spreading and, likely, for synucleopathies.

As Santiago Ramón y Cajal said “Ideas do not last long. We must do something with them.” We hope that the ideas discussed above will evolve very quickly through the use of newly emerging techniques (i.e., lab-on-a-chip, organoids, etc.) under the umbrella of new mutant mice to more fully reveal the role of PrP^C^ in neurodegeneration.

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

No potential conflicts of interest were disclosed.

**ACKNOWLEDGEMENTS**

The authors thank Tom Yohannan for editorial advice. We would also like to thank Prof.
Adriano Aguzzi for the gift of the Zurich 3 (ZH3) Prnp<sup>0/0</sup> mice and Dr. Mario Nuvolone for his comments.

**FUNDING**

This research was supported by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MEICO) (BFU2015–67777-R), the Spanish Prion Network (Prionet Spain, AGL2015–71764-REDT), the Generalitat de Catalunya (SGR2014–1218), CIBERNED (PRY-2016–2, MFDEND), La Caixa Obra Social Foundation, and La Marató de TV3 to JADR. IF was funded by the Ministerio de Economía, Industria y Competitividad (MEICO), Instituto de Salud Carlos III - Fondos FEDER, a Way to Build Europe, FIS grant PI14/00757 and CIBERNED.

**REFERENCES**

[1] Dauer W, Przedborski S. Parkinson’s disease: Mechanisms and models. Neuron 2003; 39:889-909; PMID:12971891

[2] Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billiet M, Landon M, Mayer RJ. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson’s disease, Pick’s disease, and Alzheimer’s disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol 1988; 155:9-15; PMID:2837558; https://doi.org/10.1002/path.1711550105

[3] Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003; 62:3789-97; PMID:12728231

[4] Noda K, Kitami T, Gai WP, Chegini F, Jensen PH, Fujimura T, Murayama K, Tanaka K, Mizuno Y, Hattori N. Phosphorylated IkappaBeta is a component of Lewy body of Parkinson’s disease. Biochem Biophys Res Commun 2005; 331:309-17; PMID:15845394; https://doi.org/10.1016/j.bbrc.2005.03.167

[5] Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839-40; PMID:9278044; https://doi.org/10.1038/42166

[6] Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shimozawa A, Akiyama H, Hasegawa M. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Comm 2014; 2:88; PMID:25095794; https://doi.org/10.1186/PRE ACCEPT-1296467154135944

[7] Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 2000; 97:4897-902; PMID:10781096

[8] Fujikawa H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwabu T. Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4:160-4; PMID:11813001; https://doi.org/10.1038/ncl8748

[9] Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, Lesně SE. Soluble alpha-synuclein is a novel modulator of Alzheimer’s disease pathophysiology. J Neurosci 2012; 32:10253-66; PMID:22836259; https://doi.org/10.1523/JNEUROSCI.0581-12.2012

[10] Ashe KH, Aguzzi A. Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion 2013; 7:55-9; PMID:23208281; https://doi.org/10.4161/pri.23061

[11] Erana H, Venegas V, Moreno J, Castilla J. Prion-like disorders and transmissible spongiform encephalopathies: An overview of the mechanistic features that are shared by the various disease-related misfolded proteins. Biochem Biophys Res Commun 2017; 483:1125-36; PMID:27590581; https://doi.org/10.1016/j.bbrc.2016.08.166

[12] Harbi D, Harrison PM. Classifying prion and prion-like phenomena. Prion 2014; 8:161-5; PMID:24549098; https://doi.org/10.4161/pri.27960

[13] Costanzo M, Zurzolo C. The cell biology of prion-like spread of protein aggregates: Mechanisms and implication in neurodegeneration. Biochem J 2013; 452:1-17; PMID:23614720; https://doi.org/10.1042/BJ20121898

[14] Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: Potential role in system degenerations, including Alzheimer’s disease. Neuroscience 1987; 23:389-98; PMID:2449630; https://doi.org/10.1016/0306-4522(87)90063-7

[15] Bertrand E, Lechowicz W, Szpak GM, Lewandowska E, Dymeki J, Wierzb-Bobrowicz T. Limbic neuropathology in idiopathic Parkinson’s disease with concomitant dementia. Folia Neuropathol 2004; 42:141-50; PMID:15535032

[16] Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson’s disease. Adv Anat Embryol Cell Biol 2009; 201:1-119; PMID:19230552

[17] Goedert M, Masuda-Suzukake M, Falcon B. Like prions: The propagation of aggregated tau and...
alpha-synuclein in neurodegeneration. Brain 2017; 140:266-78; PMID:27658420; https://doi.org/10.1093/brain/aww230

[18] GoedertM. Neurodegeneration. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 2015; 349:125555; PMID:26250687; https://doi.org/10.1126/science.125555

[19] Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24:197-211; PMID:12498954; https://doi.org/10.1016/S0197-4580(02)00065-9

[20] Breid S, Bernis ME, Babila JT, Garza MC, Wille H, Tamguney G. Neuroinvasion of alpha-synuclein prionoids after intraperitoneal and intraglossal inoculation. J Virol 2016; 90:9182-93; PMID:27489279; https://doi.org/10.1128/JVI.0399-16

[21] Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338:949-53; PMID:23619999; https://doi.org/10.1126/science.1227157

[22] Bernis ME, Babila JT, Breid S, Wusten KA, Wullner U, Tamguney G. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun 2015; 3:75; PMID:26612754; https://doi.org/10.1186/s40478-015-0254-7

[23] Mougenot AL, Bencsis A, Nicot S, Vulin J, Mortignat E, Verchère J, Bétemps D, Lakhdir L, Legastelois S, Baron TG. Transmission of prion strains in a transgenic mouse model overexpressing human A53T mutated alpha-synuclein. J Neuropathol Exp Neurol 2011; 70:377-85; PMID:21487306; https://doi.org/10.1097/NEN.0b013e18217d9f5f

[24] Recasens A, Dehay B, Bove J, Carballo-Carbayal I, Dovero S, Perez-Villalba A, Fernaguot PO, Blesa J, Parent A, Perier C, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014; 75:351-62; PMID:24243558; https://doi.org/10.1002/ana.24066

[25] Hasegawa M, Nonaka T, Masuda-Suzukake M. Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders. Pharmacol Ther 2017; 172:22-33; PMID:27916654; https://doi.org/10.1016/j.pharmthera.2016.11.010

[26] Cavaliere F, Cerf L, Dehay B, Ramos-Gonzalez P, De Giorgi F, Bourdax M, Bessed A, Obeso JA, Mautte C, Iach F, et al. In vitro alpha-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. Neurobiol Dis 2017; 103:101-12; PMID:28411117; https://doi.org/10.1016/j.nbd.2017.04.011

[27] Urrea L, Segura-Felhu M, Masuda-Suzukake M, Hervera A, Pedraz L, Aznar JM, et al. Involvement of cellular prion protein in alpha-synuclein transport in neurons. Mol Neurobiol 2017; Epub ahead of print; https://doi.org/10.1007/s12035-017-0451-4

[28] Freund EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourgies Y, Covert M, Melki R, Kirkegaard K, Brahic M. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol 2012; 72:517-24; PMID:23109146; https://doi.org/10.1002/ana.23747

[29] Song HL, Shim S, Kim DH, Won SH, Joo S, Kim S, Jeon NL, Yoon SY. beta-amyloid is transmitted via neuronal connections along axonal membranes. Ann Neurol 2014; 75:88-97; PMID:24114864; https://doi.org/10.1002/ana.24029

[30] Abounit S, Wu JW, Duff K, Victoria GS, Zurrolo C. Tunneling nanotubes: A possible highway in the spreading of tau and other prion-like proteins in neurodegenerative diseases. Prion 2016; 10:344-51; PMID:27715442; https://doi.org/10.1080/19336896.2016.1223003

[31] Campana V, Sarnataro D, Zurrolo C. The highways and byways of prion protein trafficking. Trends Cell Biol 2005; 15:102-11; PMID:15695097; https://doi.org/10.1016/j.tcb.2004.12.002

[32] Tardivel M, Begard S, Bousset L, Dujaardin S, Coens A, Melki R, Buée L, Colin M. Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol Commun 2016; 4:117; PMID:27809932; https://doi.org/10.1186/s40478-016-0386-4

[33] Zeinabad HA, Zarrabian A, Sabouy AA, Alizadeh AM, Falahati M. Interaction of single and multi wall carbon nanotubes with the biological systems: Tau protein and PC12 cells as targets. Sci Rep 2016; 6:26508; PMID:27216374; https://doi.org/10.1038/srep26508

[34] Dieriks BV, Park TK, Faurie C, Faull RL, Dragnun M, Curtis MA. alpha-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain periocytes from Parkinson’s disease patients. Sci Rep 2017; 7:42984; PMID:28230073; https://doi.org/10.1038/srep42984

[35] Okuda S, Uemura N, Takahashi R. alpha-synuclein fibrils propagate through tunneling nanotubes. Mov Disord 2017; 32:394; PMID:28218419; https://doi.org/10.1002/mds.26909

[36] Monsellier E, Bousset L, Melki R. alpha-synuclein and huntingtin exon 1 amyloid fibrils bind laterally to the cellular membrane. Sci Rep 2016; 6:19180; PMID:26757959; https://doi.org/10.1038/srep19180

[37] Linden R. The biological function of the prion protein: A cell surface scaffold of signaling modules.
Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: Role of N-terminal residues. J Biol Chem 2010; 285:26377-83; PMID:20576610; https://doi.org/10.1074/jbc.M110.145516

Dohler F, Sepulveda-Falla D, Krasemann S, Altermeppen H, Schluter H, Hildebrand D, Zerr I, Matschke J, Glatzel M. High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer’s disease. Brain 2014; 137:873-86; PMID:24519981; https://doi.org/10.1093/brain/awt375

Freir DB, Nicoll AJ, Klyubin I, Panico S, McDonald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, et al. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun 2011; 2:336; PMID:21654636; https://doi.org/10.1038/ncomms1341

Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457:1128-32; PMID:19242475; https://doi.org/10.1038/nature07761

Moos R, Falsig J, Mansuy IM, Aguzzi A. Prion protein mediates toxic signaling of amyloid beta. Nature 2009; 457:1128-32; PMID:19242475; https://doi.org/10.1038/nature07761

Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Renner M, Léná C, et al. alpha-synuclein assemblies sequester neuronal alpha3-Na+/K+-ATPase and impair Na+ gradient. EMBO J 2015; 34:2408-23; PMID:26323479; https://doi.org/10.15252/embj.201591397

Nuvolone M, Sorce S, Paolucci M, Aguzzi A. Prion-protein-interacting amyloid-beta oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models. J Biol Chem 2015; 290:17415-38; PMID:26018073; https://doi.org/10.1074/jbc.M115.645577

Shrivastava AN, Redeker V, Fritz N, Pieri L, Almeida LG, Spolidoro M, Liebmann T, Bousset L, Renner M, Léná C, et al. alpha-synuclein assemblies initiate by binding lymphocyte-activation gene 3. Science 2016; 353:aah3374, 1-12; https://doi.org/10.1126/science.aah3374

Nuvolone M, Herrmann M, Sorce S, Russo G, Tiberi C, Schwarz P, Minikel E, Sanoudou D, Pelczar P, Aguzzi A, et al. Strictly co-isogenic C57BL/6J-Prnp--/ mice: A rigorous resource for prion science. J Exp Med 2016; 213:313-27; PMID:26926995; https://doi.org/10.1084/jem.20151610

Nuvolone M, Sorce S, Paolucci M, Aguzzi A. Extended characterization of the novel co-isogenic C57BL/6J-Prnp--/ mouse line. Amyloid 2017; 24:36-7; PMID:28434290; https://doi.org/10.1080/13506129.2017.1289913

Vinches S, Vergara C, Nicolas O, Sanclimens G, Merino S, Varon S, Acosta GA, Albericio F, Royo M, Del Río JA, et al. Neurotoxicity of prion peptides mimicking the central domain of the cellular prion protein.
[57] Burre J, Sharma M, Sudhof TC. Cell biology and Pathophysiology of alpha-Synuclein. Cold Spring Harb Perspect Med 2017; Epub ahead of print; PMID:28108534; https://doi.org/10.1101/cshperspect.a024091

[58] Chung E, Ji Y, Sun Y, Kascak RJ, Kascak RB, Mehta PD, Strittmatter SM, Wisniewski T. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer’s disease model mouse. BMC Neurosci 2010; 11:130; PMID:20946660; https://doi.org/10.1186/1471-2202-11-130